Published in Phytother Res on December 01, 2010
AMP-activated protein kinase inhibits vascular smooth muscle cell proliferation and migration and vascular remodeling following injury. Am J Physiol Heart Circ Physiol (2012) 1.00
Genome-wide transcriptome and proteome analysis on different developmental stages of Cordyceps militaris. PLoS One (2012) 0.97
Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer. Mediators Inflamm (2012) 0.91
Anti-inflammatory effects of cordycepin in lipopolysaccharide-stimulated RAW 264.7 macrophages through Toll-like receptor 4-mediated suppression of mitogen-activated protein kinases and NF-κB signaling pathways. Drug Des Devel Ther (2014) 0.87
Astrocyte-derived tissue transglutaminase interacts with fibronectin: a role in astrocyte adhesion and migration? PLoS One (2011) 0.85
Cordycepin induces cell cycle arrest and apoptosis by inducing DNA damage and up-regulation of p53 in Leukemia cells. Cell Cycle (2015) 0.84
Apoptosis and inhibition of proliferation of cancer cells induced by cordycepin. Oncol Lett (2015) 0.83
TNF-α promotes breast cancer cell migration and enhances the concentration of membrane-associated proteases in lipid rafts. Cell Oncol (Dordr) (2016) 0.82
Cordycepin inhibits LPS-induced inflammatory and matrix degradation in the intervertebral disc. PeerJ (2016) 0.79
Toxicity evaluation of cordycepin and its delivery system for sustained in vitro anti-lung cancer activity. Nanoscale Res Lett (2015) 0.79
Cordycepin regulates GSK-3β/β-catenin signaling in human leukemia cells. PLoS One (2013) 0.77
Antitumor activity of kielmeyera coriacea leaf constituents in experimental melanoma, tested in vitro and in vivo in syngeneic mice. Adv Pharm Bull (2014) 0.75
Immune Modulation From Five Major Mushrooms: Application to Integrative Oncology. Integr Med (Encinitas) (2014) 0.75
Pharmacological and therapeutic potential of Cordyceps with special reference to Cordycepin. 3 Biotech (2013) 0.75
Detailed analysis of patients with metastasis to the prostatic anterior fat pad lymph nodes: a multi-institutional study. J Urol (2013) 2.76
Mouse DNA contamination in human tissue tested for XMRV. Retrovirology (2010) 2.65
Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer (2010) 2.41
Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol (2010) 2.37
K-RAS transformation in prostate epithelial cell overcomes H2O2-induced apoptosis via upregulation of gamma-glutamyltransferase-2. Toxicol In Vitro (2012) 2.03
Differential activation of mitogenic signaling pathways in aortic smooth muscle cells deficient in superoxide dismutase isoforms. Arterioscler Thromb Vasc Biol (2005) 1.84
Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J Biol Chem (2004) 1.84
Impact of obesity in patients with urolithiasis and its prognostic usefulness in stone recurrence. J Urol (2007) 1.81
Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J Urol (2008) 1.75
Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: complete regression of hepatoma growth and metastasis by dual mechanism. FASEB J (2004) 1.73
Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol (2004) 1.65
RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol (2005) 1.64
Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance. Urology (2013) 1.63
The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer. Cell Cycle (2012) 1.56
Gene signatures for the prediction of response to Bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers. Clin Cancer Res (2010) 1.52
Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun (2004) 1.41
Favorable risk factors in patients with positive surgical margin after robot-assisted radical prostatectomy. Can J Urol (2014) 1.40
EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin Cancer Res (2011) 1.33
A case of vesical and scrotal sparganosis presenting as a scrotal mass. Korean J Parasitol (2010) 1.28
Mutational hot spot in the DSPP gene causing dentinogenesis imperfecta type II. Hum Genet (2004) 1.26
Bladder Cancer Working Group report. Jpn J Clin Oncol (2010) 1.21
Environmental factors promoting bladder cancer. Curr Opin Urol (2009) 1.14
A four-gene signature predicts disease progression in muscle invasive bladder cancer. Mol Med (2011) 1.14
Diagnosis of bladder cancer and prediction of survival by urinary metabolomics. Oncotarget (2014) 1.13
Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol (2012) 1.12
HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: array-based DNA methylation and expression profiling. Int J Cancer (2013) 1.11
Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol (2006) 1.08
Natural history of asymptomatic renal stones and prediction of stone related events. J Urol (2012) 1.07
Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer. Urology (2009) 1.06
A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53. Sci Signal (2013) 1.04
Cancer gene therapy using adeno-associated virus vectors. Front Biosci (2008) 1.04
Honokiol causes the p21WAF1-mediated G(1)-phase arrest of the cell cycle through inducing p38 mitogen activated protein kinase in vascular smooth muscle cells. FEBS Lett (2006) 1.01
New porcine microRNA genes found by homology search. Genome (2006) 1.01
Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. Mol Cancer (2011) 1.00
Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion. Int J Cancer (2013) 1.00
Resveratrol inhibits TNF-alpha-induced proliferation and matrix metalloproteinase expression in human vascular smooth muscle cells. J Nutr (2005) 1.00
Cordycepin causes p21WAF1-mediated G2/M cell-cycle arrest by regulating c-Jun N-terminal kinase activation in human bladder cancer cells. Arch Biochem Biophys (2009) 0.99
Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology (2005) 0.99
Induction of apoptosis and autophagy by sodium selenite in A549 human lung carcinoma cells through generation of reactive oxygen species. Toxicol Lett (2012) 0.99
Cell-Free microRNA-214 From Urine as a Biomarker for Non-Muscle-Invasive Bladder Cancer. Korean J Urol (2013) 0.98
Gleditsia sinensis thorn extract inhibits human colon cancer cells: the role of ERK1/2, G2/M-phase cell cycle arrest and p53 expression. Phytother Res (2010) 0.97
Body mass index influences prostate-specific antigen in men younger than 60 years of age. Int J Urol (2007) 0.96
MicroRNAs in prostate cancer. Prostate Int (2012) 0.96
c-Jun N-terminal kinase 1 is required for cordycepin-mediated induction of G2/M cell-cycle arrest via p21WAF1 expression in human colon cancer cells. Food Chem Toxicol (2009) 0.96
Epigenetic markers as promising prognosticators for bladder cancer. Int J Urol (2008) 0.95
Combined aberrant expression of E-cadherin and S100A4, but not β-catenin is associated with disease-free survival and overall survival in colorectal cancer patients. Diagn Pathol (2013) 0.95
Anti-inflammatory effects of cordycepin via suppression of inflammatory mediators in BV2 microglial cells. Int Immunopharmacol (2010) 0.95
Inhibition of migration and invasion of LNCaP human prostate carcinoma cells by cordycepin through inactivation of Akt. Int J Oncol (2012) 0.95
Panax ginseng improves survival and sperm quality in guinea pigs exposed to 2,3,7,8-tetrachlorodibenzo- p-dioxin. BJU Int (2004) 0.94
Apoptosis induction of human bladder cancer cells by sanguinarine through reactive oxygen species-mediated up-regulation of early growth response gene-1. PLoS One (2013) 0.94
Inhibition of cell motility and invasion by HangAmDan-B in NCI-H460 human non-small cell lung cancer cells. Oncol Rep (2011) 0.93
Role of the p38 MAPK signaling pathway in mediating interleukin-28A-induced migration of UMUC-3 cells. Int J Mol Med (2012) 0.93
Signaling pathway for TNF-alpha-induced MMP-9 expression: mediation through p38 MAP kinase, and inhibition by anti-cancer molecule magnolol in human urinary bladder cancer 5637 cells. Int Immunopharmacol (2008) 0.93
Epigallocatechin-3-gallate causes the p21/WAF1-mediated G(1)-phase arrest of cell cycle and inhibits matrix metalloproteinase-9 expression in TNF-alpha-induced vascular smooth muscle cells. Arch Biochem Biophys (2005) 0.93
Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels. J Korean Med Sci (2011) 0.92
Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination. Cancer Res (2009) 0.92
mRNA Expression of S100A8 as a Prognostic Marker for Progression of Non-Muscle-Invasive Bladder Cancer. Korean J Urol (2010) 0.92
TNF-alpha regulates vascular smooth muscle cell responses in genetic hypertension. Int Immunopharmacol (2009) 0.92
Forkhead box O-class 1 and forkhead box G1 as prognostic markers for bladder cancer. J Korean Med Sci (2009) 0.91
Increased expression of sonic hedgehog and altered methylation of its promoter region in gastric cancer and its related lesions. Mod Pathol (2006) 0.91
Requirement for Ras/Raf/ERK pathway in naringin-induced G1-cell-cycle arrest via p21WAF1 expression. Carcinogenesis (2008) 0.91
Induction of interleukin-6 expression by bone morphogenetic protein-6 in macrophages requires both SMAD and p38 signaling pathways. J Biol Chem (2010) 0.90
Melittin suppresses HIF-1α/VEGF expression through inhibition of ERK and mTOR/p70S6K pathway in human cervical carcinoma cells. PLoS One (2013) 0.90
BMP-6 in renal cell carcinoma promotes tumor proliferation through IL-10-dependent M2 polarization of tumor-associated macrophages. Cancer Res (2013) 0.90
Naringenin up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer A549 cells. Mol Nutr Food Res (2011) 0.90
Sequence variants of Toll-like receptor 4 (TLR4) and the risk of prostate cancer in Korean men. World J Urol (2011) 0.90
Bmal1 suppresses cancer cell invasion by blocking the phosphoinositide 3-kinase-Akt-MMP-2 signaling pathway. Oncol Rep (2013) 0.90
Rare exonic minisatellite alleles in MUC2 influence susceptibility to gastric carcinoma. PLoS One (2007) 0.89
Melittin has an inhibitory effect on TNF-α-induced migration of human aortic smooth muscle cells by blocking the MMP-9 expression. Food Chem Toxicol (2012) 0.89
Gleditsia sinensis thorn extract inhibits proliferation and TNF-α-induced MMP-9 expression in vascular smooth muscle cells. Am J Chin Med (2012) 0.89
Interleukin-5 enhances the migration and invasion of bladder cancer cells via ERK1/2-mediated MMP-9/NF-κB/AP-1 pathway: involvement of the p21WAF1 expression. Cell Signal (2013) 0.89
Induction of apoptosis and inhibition of telomerase activity by aqueous extract from Platycodon grandiflorum in human lung carcinoma cells. Pharmacol Res (2005) 0.87
Mdm2 increases cellular invasiveness by binding to and stabilizing the Slug mRNA. Cancer Lett (2013) 0.87
Anti-inflammatory effects of Polygala tenuifolia root through inhibition of NF-κB activation in lipopolysaccharide-induced BV2 microglial cells. J Ethnopharmacol (2011) 0.87
Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage. Anticancer Drugs (2009) 0.87